ArticleJournal of inflammation research2020
Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19).
Article in Journal of inflammation research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review.Frontiers in medicine · 2021Pooled it
- Elevated De Ritis Ratio Is Associated With Poor Prognosis in COVID-19: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Article
- Association Between Chromium and Lead Exposure and Liver Injury Biomarkers Among Adults in Addis Ababa, Ethiopia.Environmental health insights · 2025Article
- Gastrointestinal Manifestation and In-hospital Mortality among End-Stage Renal Disease Patients with COVID-19: A Single-center Retrospective Cohort Study.Acta medica Philippina · 2025Article
- Emergence of coinfection with visceral Leishmania infantum in COVID-19 patients: a case‒control field study in an endemic area of visceral leishmaniasis in Iran.BMC infectious diseases · 2024Article
- Liver and Inflammatory Biomarkers Are Related to High Mortality in Hospitalized Patients with COVID-19 in Brazilian Amazon Region.Life (Basel, Switzerland) · 2024Article
- Predictors of Mortality among End-Stage Renal Disease Patients with COVID-19 Admitted in a Philippine Tertiary Government Hospital: A Retrospective Cohort Study.Acta medica Philippina · 2024Article
- Biosynthesized Nanosilver from Ginger Extract Exhibits Antioxidant and Hepatic Responses duringACS omega · 2023Article
- Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population.Current microbiology · 2023Article
- Acute-on-chronic liver failure in patients with severe acute respiratory syndrome coronavirus 2 infection.World journal of hepatology · 2023Review
- COVID-19, HIV, and Cryptococcal Meningitis Coinfections with Abnormal Laboratory Findings.Case reports in pulmonology · 2023Article
- Genetic diversity ofThe Egyptian journal of medical human genetics · 2023Article
- Natural Products as a Potential Source of Promising Therapeutics for COVID-19 and Viral Diseases.Evidence-based complementary and alternative medicine : eCAM · 2023Review
- Liver injury in COVID-19: A minireview.World journal of gastroenterology · 2022Review
- Biosensors based detection of novel biomarkers associated with COVID-19: Current progress and future promise.Biosensors & bioelectronics: X · 2022Review
- Biomarker based biosensors: An opportunity for diagnosis of COVID-19.Reviews in medical virology · 2022Review
- Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges.Journal of family medicine and primary care · 2022Review
- Factors Affecting the Self-Isolation Monitoring Program for COVID-19 Patients at the Universitas Indonesia Hospital.Journal of environmental and public health · 2022Article
- Zinc as a Drug for Wilson's Disease, Non-Alcoholic Liver Disease and COVID-19-Related Liver Injury.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCoronavirus disease 2019 (COVID-19) emerged in China and spread worldwide. In this study, we assessed the characteristics of markers of the liver in patients with COVID-19 to provide new insights in improving clinical treatment. PATIENTS AND
methodsWe recruited 279 patients who confirmed COVID-19 and the data of liver biomarkers and complete blood count of patients were defined as the day onset when the patients admitted to the hospital.
resultsThe average of LDH value was 621.29 U/L in all patients with COVID-19, and CPK was 286.90 U/L. The average AST was 44.03 U/L in all patients, and ALT was 31.14 U/L. The AST/ALT ratio was 1.64 in all patients. The measurement of CRP was increased by 79.93% in all patients. Average ALT and AST values of patients with elevated ALT were significantly increased in comparison to patients with normal ALT (
conclusionHepatic injury and abnormal liver enzymes related to COVID-19 infection is an acute non-specific inflammation alteration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.